Lombard Odier Asset Management (USA)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,300	Closed	-$2.23M	–	234
2019 Q1	$2.23M	Buy	7,300 +339	+5%	+$91.5K	0.18%	121
2018 Q4	$1.62M	Sell	6,961 -8,039	-54%	-$2.16M	0.13%	149
2018 Q3	$4.7M	Buy	+15,000	New	+$4.66M	0.34%	94
2017 Q4	–	Sell	-15,000	Closed	-$3.33M	–	219
2017 Q3	$3.33M	Buy	15,000 +5,000	+50%	+$1.13M	0.24%	107
2017 Q2	$2.26M	Buy	+10,000	New	+$2.18M	0.18%	130

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s BIO Position: Q2 2019 in Review

Lombard Odier Asset Management (USA) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2019, closing a stake of 7,300 shares — an estimated $2.23M sold.

Lombard Odier Asset Management (USA) first reported a position in BIO in Q2 2017 and held it in 5 quarters. The position peaked at $4.7M in Q3 2018. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

Lombard Odier Asset Management (USA) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2019 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 7,300 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $2.23M.
Lombard Odier Asset Management (USA) first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 5 quarters.
Lombard Odier Asset Management (USA)'s Bio-Rad Laboratories Class A position peaked at $4.7M in Q3 2018.
330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2019, filed 14 Aug 2019.